BACKGROUND: An increasing number of studies have demonstrated a role for the tumor microenvironment in tumorigenesis, disease progression, and therapeutic response. This present study aimed to screen the significant immune-related genes and their possible role in the prognosis of breast cancer (BRCA). METHODS: The transcriptome data and clinical data of breast cancer were collected from The Cancer Genome Atlas (TCGA), and the immune scores and stromal scores were calculated by ESTIMATE algorithm. The differentially expressed genes were screened base on immune and stromal scores (high score vs. low score), than the intersected genes were used for subsequent functional enrichment analysis and protein-protein interaction (PPI) analysis. Furthermore, the key gene was identified by the intersection of the hub genes of PPI network and the prognostic genes of breast cancer. Finally, we explored the infiltration of immune cells of BRCA base on the CIBERSORT algorithm, and analysis the relationship between key gene and immune cells. RESULTS: High levels of CD52 expression were detected in the early stages of breast cancer and were associated with favorable prognosis. Overexpression of CD52 led to higher infiltrations of M1 macrophages, monocytes, T follicular helper cells, and resting memory CD4 T cells. Downregulation of CD52 resulted in high infiltrations of M2 macrophages. Therefore, high expression of CD52 may negatively regulate the infiltration of M2 macrophages but accelerate the infiltration of anti-cancer immune cells, and thus, high expression of CD52 may have a protective effect in breast cancer patients. CONCLUSIONS: CD52 can increase the infiltration of anti-cancer immune cells but inhibit the infiltration of M2 macrophages, thereby improving the prognosis of breast cancer patients. 2021 Gland Surgery. All rights reserved.
BACKGROUND: An increasing number of studies have demonstrated a role for the tumor microenvironment in tumorigenesis, disease progression, and therapeutic response. This present study aimed to screen the significant immune-related genes and their possible role in the prognosis of breast cancer (BRCA). METHODS: The transcriptome data and clinical data of breast cancer were collected from The Cancer Genome Atlas (TCGA), and the immune scores and stromal scores were calculated by ESTIMATE algorithm. The differentially expressed genes were screened base on immune and stromal scores (high score vs. low score), than the intersected genes were used for subsequent functional enrichment analysis and protein-protein interaction (PPI) analysis. Furthermore, the key gene was identified by the intersection of the hub genes of PPI network and the prognostic genes of breast cancer. Finally, we explored the infiltration of immune cells of BRCA base on the CIBERSORT algorithm, and analysis the relationship between key gene and immune cells. RESULTS: High levels of CD52 expression were detected in the early stages of breast cancer and were associated with favorable prognosis. Overexpression of CD52 led to higher infiltrations of M1 macrophages, monocytes, T follicular helper cells, and resting memory CD4 T cells. Downregulation of CD52 resulted in high infiltrations of M2 macrophages. Therefore, high expression of CD52 may negatively regulate the infiltration of M2 macrophages but accelerate the infiltration of anti-cancer immune cells, and thus, high expression of CD52 may have a protective effect in breast cancer patients. CONCLUSIONS: CD52 can increase the infiltration of anti-cancer immune cells but inhibit the infiltration of M2 macrophages, thereby improving the prognosis of breast cancer patients. 2021 Gland Surgery. All rights reserved.
Entities:
Keywords:
Breast cancer; CD52; bioinformatics; immune infiltrates
Authors: C E Dearden; E Matutes; B Cazin; G E Tjønnfjord; A Parreira; B Nomdedeu; P Leoni; F J Clark; D Radia; S M Rassam; T Roques; N Ketterer; V Brito-Babapulle; M J Dyer; D Catovsky Journal: Blood Date: 2001-09-15 Impact factor: 22.113
Authors: Alessandra Ferrajoli; Susan M O'Brien; Jorge E Cortes; Francis J Giles; Deborah A Thomas; Stefan Faderl; Razelle Kurzrock; Susan Lerner; Dimitrios P Kontoyiannis; Michael J Keating Journal: Cancer Date: 2003-08-15 Impact factor: 6.860
Authors: Gabriela Alexe; Gul S Dalgin; Daniel Scanfeld; Pablo Tamayo; Jill P Mesirov; Charles DeLisi; Lyndsay Harris; Nicola Barnard; Maritza Martel; Arnold J Levine; Shridar Ganesan; Gyan Bhanot Journal: Cancer Res Date: 2007-11-15 Impact factor: 12.701
Authors: Jeanette Lundin; Hans Hagberg; Roland Repp; Eva Cavallin-Ståhl; Susanne Fredén; Gunnar Juliusson; Eija Rosenblad; Geir Tjønnfjord; Tom Wiklund; Anders Osterborg Journal: Blood Date: 2003-01-23 Impact factor: 22.113
Authors: Evgeniy B Eruslanov; Pratik S Bhojnagarwala; Jon G Quatromoni; Tom Li Stephen; Anjana Ranganathan; Charuhas Deshpande; Tatiana Akimova; Anil Vachani; Leslie Litzky; Wayne W Hancock; José R Conejo-Garcia; Michael Feldman; Steven M Albelda; Sunil Singhal Journal: J Clin Invest Date: 2014-11-10 Impact factor: 14.808
Authors: L Faucheux; M Grandclaudon; M Perrot-Dockès; P Sirven; F Berger; A S Hamy; V Fourchotte; A Vincent-Salomon; F Mechta-Grigoriou; F Reyal; A Scholer-Dahirel; M Guillot-Delost; V Soumelis Journal: Oncoimmunology Date: 2019-06-24 Impact factor: 8.110